Mirum Pharmaceuticals Inc (MIRM)
43.48
-0.21
(-0.48%)
USD |
NASDAQ |
Nov 21, 16:00
43.48
0.00 (0.00%)
After-Hours: 20:00
Mirum Pharmaceuticals Enterprise Value: 2.121B for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 2.121B |
| November 19, 2024 | 2.044B |
| November 18, 2024 | 2.012B |
| November 15, 2024 | 2.159B |
| November 14, 2024 | 2.244B |
| November 13, 2024 | 2.132B |
| November 12, 2024 | 2.053B |
| November 11, 2024 | 2.021B |
| November 08, 2024 | 2.039B |
| November 07, 2024 | 1.994B |
| November 06, 2024 | 1.994B |
| November 05, 2024 | 1.976B |
| November 04, 2024 | 1.964B |
| November 01, 2024 | 1.961B |
| October 31, 2024 | 1.868B |
| October 30, 2024 | 1.903B |
| October 29, 2024 | 1.897B |
| October 28, 2024 | 1.920B |
| October 25, 2024 | 1.889B |
| October 24, 2024 | 1.911B |
| October 23, 2024 | 1.866B |
| October 22, 2024 | 1.927B |
| October 21, 2024 | 1.911B |
| October 18, 2024 | 1.916B |
| October 17, 2024 | 1.909B |
| Date | Value |
|---|---|
| October 16, 2024 | 1.931B |
| October 15, 2024 | 1.928B |
| October 14, 2024 | 1.931B |
| October 11, 2024 | 1.947B |
| October 10, 2024 | 1.869B |
| October 09, 2024 | 1.839B |
| October 08, 2024 | 1.890B |
| October 07, 2024 | 1.882B |
| October 04, 2024 | 1.906B |
| October 03, 2024 | 1.923B |
| October 02, 2024 | 2.013B |
| October 01, 2024 | 1.948B |
| September 30, 2024 | 1.894B |
| September 27, 2024 | 1.882B |
| September 26, 2024 | 1.875B |
| September 25, 2024 | 1.889B |
| September 24, 2024 | 1.888B |
| September 23, 2024 | 1.886B |
| September 20, 2024 | 1.888B |
| September 19, 2024 | 1.906B |
| September 18, 2024 | 1.837B |
| September 17, 2024 | 1.951B |
| September 16, 2024 | 1.957B |
| September 13, 2024 | 1.991B |
| September 12, 2024 | 1.991B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
33.52M
Minimum
Nov 25 2019
2.244B
Maximum
Nov 14 2024
737.61M
Average
543.94M
Median
Enterprise Value Benchmarks
| Arcutis Biotherapeutics Inc | 1.066B |
| Cytokinetics Inc | 5.529B |
| Amicus Therapeutics Inc | 3.005B |
| MannKind Corp | 1.874B |
| TG Therapeutics Inc | 4.752B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.24M |
| Revenue (Quarterly) | 90.38M |
| Total Expenses (Quarterly) | 103.06M |
| EPS Diluted (Quarterly) | -0.30 |
| Gross Profit Margin (Quarterly) | 76.98% |
| Profit Margin (Quarterly) | -15.75% |
| Earnings Yield | -4.76% |
| Normalized Earnings Yield | -4.760 |